Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 30:848-853, 2007
DOI: 10.2337/dc06-2000
© 2007 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rathmann, W.
Right arrow Articles by Giani, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rathmann, W.
Right arrow Articles by Giani, G.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Epidemiology/Health Services/Psychosocial Research
Original Article

Trends in Outpatient Prescription Drug Costs in Diabetic Patients in Germany, 1994–2004

Wolfgang Rathmann, MD, MSPH, Burkhard Haastert, PHD, Andrea Icks, MD, MPH, DRPH and Guido Giani, PHD

From the Institute of Biometrics and Epidemiology, German Diabetes Center, Leibniz Institute at the Heinrich-Heine-University, Düsseldorf, Germany

Address correspondence and reprint requests to Dr. Wolfgang Rathmann, MSPH (USA), Institute of Biometrics and Epidemiology, German Diabetes Center, Auf'm Hennekamp 65, D-40225 Düsseldorf, Germany. E-mail: rathmann{at}ddz.uni-duesseldorf.de

OBJECTIVE—New antidiabetic medications have been introduced during the last decade, but their impact on health care cost is largely unknown. Prescription costs in diabetic patients in primary care in Germany were evaluated (1994–2004).

RESEARCH DESIGN AND METHODS—A total of 46,017 diabetic patients and 46,017 age- and sex-matched control subjects in 400 nationwide practices (2004) were compared with 29,956 diabetic patients and 13,226 control subjects (361 practices) in 1994 (data from IMS HEALTH). Inflation-adjusted age- and sex-standardized costs (ex-manufacturer prices) were calculated.

RESULTS—Mean annual total prescription costs per diabetic patient were {euro}559 in 2004 ({euro}372 in 1994), equaling a 60% (standardized) increase (P < 0.01). Average costs for antidiabetic medication were {euro}172 in 2004, a 100% increase (P < 0.01). The major antidiabetic cost factor was insulin and analogs, which accounted for 22% of total drug costs in diabetic patients in 2004 (17% in 1994). All oral antidiabetic drugs together accounted for 8% of total costs (6% in 1994). New drugs (glitazones, glinides, and insulins) accounted for 15% of total costs (40% of antidiabetic drugs) in 2004. A 40% increase ({euro}387 vs. 286) in all non–diabetes-related drugs was due mainly to cardiovascular and lipid-lowering drugs. In nondiabetic patients, only a 30% cost increase was found ({euro}210 vs. 147; P < 0.01).

CONCLUSIONS—Prescription drug costs among diabetic patients increased 60% during the last decade, which was twofold higher than the increase in nondiabetic patients. New types of antidiabetic drugs accounted for a substantial cost share of the overproportional increase for diabetes treatment. Progress in pharmacological therapy is a key driver of drug expenditure growth in diabetes treatment.

Abbreviations: ATC, anatomical therapeutic chemical classification system • SMBG, self-monitoring blood glucose


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.